drugset / Trial / NCT05050097
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Timeline
- Start
- 2021-09-22
- Primary completion
- 2025-03-31
- Completion
- 2027-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Pomalidomide | Other / unclassified | — | Oral |
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |